A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution before reaching a scientifically supported conclusion.
In an investigation involving cetirizine dihydrochloride oral solution, the root cause of a low HPLC assay result was traced to an insufficient quantity of water specified for dissolving the active pharmaceutical ingredient (API). The investigation led to a controlled batch manufacturing record (BMR) revision, followed by satisfactory results in subsequent batches, three-batch change-control stability studies and process revalidation.
This case demonstrates how a structured OOS investigation can identify a manufacturing-related cause and support corrective action with follow-up evidence.
1. Start With the OOS Result, Not an Assumption
When the HPLC assay result fell below specification, the investigation began with a review of the analytical process and associated records.
An OOS result should not automatically be attributed to analyst error, instrument malfunction or manufacturing failure. Investigators must first assess the available evidence and determine whether the result has an identifiable laboratory-related cause.
Relevant checks can include chromatograms, integration, calculations, reference and sample preparations, system suitability, instrument performance and laboratory records.
Where the laboratory review does not establish an assignable analytical cause, the investigation should expand to manufacturing records and process-related factors. The original result must remain part of the investigation, and repeat testing must follow an approved, scientifically justified approach rather than an attempt to obtain a passing result [1].
2. Review the Manufacturing Instructions
The investigation identified a critical detail in the batch manufacturing record. The instruction specified that the API should be dissolved separately in 5 litres of water.
The investigation team reviewed the API quantity, the specified water volume and the available solubility information. The key question was whether the prescribed quantity of water was sufficient for the amount of cetirizine dihydrochloride being processed.
This review highlighted a potential weakness in the manufacturing instruction: the specified solvent volume did not adequately support dissolution of the API quantity used in the process.
The finding shifted the investigation from simply reviewing the HPLC result to examining whether the manufacturing procedure could consistently produce a homogeneous solution [2].
3. Use Solubility Information and Practical Trials
The QC team consulted the British Pharmacopoeia (BP) for solubility information on cetirizine dihydrochloride [3]. The team also conducted two to three practical trials using different API quantities and different volumes of diluent.
These trials helped assess whether the prescribed water volume was adequate for the API quantity involved. Although the material appeared dissolved on visual inspection, small undissolved particles remained.
This observation was important. A solution that appears clear or adequately mixed does not, by appearance alone, establish that the API has dissolved completely. The investigation therefore considered both the applicable solubility information and the findings from practical trials.
The combined evidence supported the conclusion that 5 litres of water was insufficient under the investigated conditions. Increasing the water volume to 10 litres provided the basis for correcting the manufacturing instruction.
4. Establish the Link Between Incomplete Dissolution and Low Assay
The investigation linked the inadequate water quantity and incomplete API dissolution with the low HPLC assay result.
This distinction matters because an HPLC method may perform as intended while the sample entering the analytical process does not adequately represent the material manufactured. An investigation that focuses exclusively on instrument performance can miss a process-related cause.
In this case, the laboratory findings, review of solubility information and practical trials directed attention to the manufacturing step used to dissolve the API.
The root cause was therefore addressed through the manufacturing procedure rather than by changing the analytical method without scientific justification.
5. Implement Corrective Action Through Change Control
Following the investigation, the BMR was revised through the formal change-control process. The specified water quantity for dissolving the API was increased from 5 litres to 10 litres.
This correction addressed the identified deficiency in the manufacturing instruction. It also provided a controlled record of the revised process requirement, supporting consistent execution in future batches.
Under a pharmaceutical quality system, such changes should undergo appropriate review and approval before implementation. The scope of verification should reflect the nature of the change and its potential effect on product quality.
ICH Q10 describes a pharmaceutical quality system that supports change management, continual improvement and evaluation of the effectiveness of corrective and preventive actions [4].
6. Verify the Effectiveness of the Change
A corrective action is not adequately demonstrated by an updated document alone. The manufacturer must also evaluate whether the change achieves its intended purpose and maintains product quality.
In this case, subsequent batches produced satisfactory assay results after implementation of the revised water quantity. The company also conducted change-control stability studies on three batches and revalidated the manufacturing process. According to the investigation outcome, these activities produced satisfactory results.
These follow-up activities provided additional evidence that the revised manufacturing instruction was suitable and that the change did not introduce an identified quality concern during the evaluation.
The broader lesson is that effectiveness assessment should be appropriate to the change and supported by documented evidence. Depending on the circumstances, this may include subsequent batch results, stability data, process-validation or revalidation outcomes, and review of relevant deviations or recurring trends.
7. Key Lessons for QC and Manufacturing Teams
This investigation highlights several practical lessons:
- Do not stop at laboratory checks. When the evidence does not establish a laboratory cause, extend the investigation to manufacturing and process variables.
- Evaluate the quantity of solvent against the API load. Manufacturing instructions should provide an adequate and justified quantity of solvent for the specified process.
- Do not rely on visual appearance alone. Apparent dissolution does not independently demonstrate that the API has dissolved completely.
- Use evidence to establish root cause. Relevant pharmacopoeial information, practical trials and batch records can help connect a process deficiency with an OOS result.
- Control the correction formally. Update the BMR through approved change control rather than relying on an informal instruction.
- Verify the outcome. Subsequent batch results, stability studies and process revalidation can provide complementary evidence that a change has achieved its intended objective.
Effective OOS investigations require collaboration between QC, manufacturing, quality assurance and other relevant technical functions. Each function contributes different evidence, but the final conclusion must remain scientifically justified and traceable to the investigation record.
Conclusion
The cetirizine dihydrochloride oral-solution case illustrates how a low HPLC assay OOS result can reveal a weakness in a manufacturing instruction rather than an analytical failure.
Review of BP solubility information and practical trials helped identify the inadequacy of the original 5-litre water quantity. A formal BMR change increased the quantity to 10 litres, after which subsequent batch assay results, three-batch change-control stability studies and process revalidation were satisfactory.
The central lesson is straightforward: a defensible OOS investigation identifies the underlying cause, implements a controlled correction and evaluates whether the change works. This approach supports reliable analytical results, consistent manufacturing and a stronger pharmaceutical quality system.
Author Bio
